Drug facts
BrandSancuso (Granisetron)
No generic version of Sancuso is approved; no Sancuso patent or exclusivity is listed in the Orange Book.
Sancuso was first approved by the FDA on 09/12/2008 under NDA 022198; the application holder is Apotex Inc.
The latest NADAC for SANCUSO 3.1 MG/24 HR PATCH is $686.64 per unit (as of 10/28/2026).
Holder Apotex IncApplication NDA 022198Approved 09/12/2008
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No Sancuso patent listed in the Orange Book Orange Book
02Competition
- Generics
- No generic approved Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Sancuso profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $686.64 per unitSANCUSO 3.1 MG/24 HR PATCH, as of 10/28/2026 CMS NADAC
04Product
- Application holder
- Apotex Inc Orange Book
- Application
- NDA 022198 Orange Book
- First approved
- 09/12/2008 Orange Book
- Dosage forms
- film, extended release
- Routes
- transdermal
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.